MAM
RLMD icon

Martingale Asset Management’s Relmada Therapeutics RLMD Stock Holding History

Martingale Asset Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,806
Closed -$374K – 876
2022
Q1 		$374K Sell
13,806
-3,700
-21% -$76.5K 0.01% 693
2021
Q4 		$396K Sell
17,506
-100
-0.6% -$2.22K 0.01% 687
2021
Q3 		$463K Buy
17,606
+10,100
+135% +$270K 0.01% 683
2021
Q2 		$241K Hold
7,506
– – ﹤0.01% 768
2021
Q1 		$265K Sell
7,506
-100
-1% -$3.5K ﹤0.01% 770
2020
Q4 		$245K Sell
7,606
-29,900
-80% -$1.03M ﹤0.01% 791
2020
Q3 		$1.41M Buy
+37,506
New +$1.45M 0.02% 523

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Martingale Asset Management's RLMD Position: Q2 2022 in Review

Martingale Asset Management sold out of Relmada Therapeutics (RLMD) in Q2 2022, closing a stake of 13,806 shares — an estimated $374K sold.

Martingale Asset Management first reported a position in RLMD in Q3 2020 and held it in 7 quarters. The position peaked at $1.41M in Q3 2020. 113 funds tracked by Wall St. Rank hold RLMD as of Q2 2022.

  • Martingale Asset Management reported no remaining Relmada Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Martingale Asset Management sold 13,806 Relmada Therapeutics shares in Q2 2022, an estimated $374K.
  • Martingale Asset Management first reported a position in Relmada Therapeutics in Q3 2020 and held it in 7 quarters.
  • Martingale Asset Management's Relmada Therapeutics position peaked at $1.41M in Q3 2020.
  • 113 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2022.

Based on Martingale Asset Management's 13F filing for Q2 2022, filed 11 Aug 2022.